Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-02

Study Completion Date

2017-03-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates anastrazole and clomiphene in the improvement in hypogonadal symptoms and erectile function. Each subject will receive Anastrazole 1 mg/day, clomiphene 25 mg/day and placebo in randomized schedule of 8 week intervals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

NCT00962637

Secondary Hypogonadism

COMPLETED PHASE3

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

NCT00179517

Seizure Disorder Hypogonadism Erectile Dysfunction

COMPLETED PHASE2

Pharmacokinetic Study to Determine Time to Steady-state

NCT00911586

Male Hypogonadism Primary Hypogonadism Secondary Hypogonadism

COMPLETED PHASE2

Androxal in Male Infertility

NCT02160704

Infertility

WITHDRAWN PHASE2/PHASE3

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

NCT02651688

Acquired Hypogonadotropic Hypogonadism Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aromatase inhibitors (AI) (Anastrazole) and selective estrogen receptor modifiers (SERMS)(clomiphene) increase testosterone production through stimulation of the hypothalamic pituitary axis. While these drugs both reduce the feedback inhibition of estrogen on the pituitary, SERMs cause an increase in serum estradiol, whereas AIs reduce estradiol levels. Using these medications, we can obtain therapeutic testosterone levels with either an increase or decrease in estradiol levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypogonadism, Male

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anastrazole-clomiphene-placebo

anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks

Group Type OTHER

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

anastrazole-placebo-clomiphene

anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks

Group Type OTHER

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

clomiphene-anastrazole-placebo

clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks

Group Type OTHER

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

clomiphene-placebo-anastrazole

clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks

Group Type OTHER

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

placebo-clomiphene-anastrazole

placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks

Group Type OTHER

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

placebo-anastrazole-clomiphene

placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks

Group Type OTHER

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anastrozole 1mg

Intervention Type DRUG

Clomiphene Citrate 25mg

Intervention Type DRUG

Placebo - Cap

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men age 18-70
2. Baseline morning Testosterone 150-350 ng/dL x2
3. leutenizing hormone (LH) 1.5-9.2 miU/mL, Follicle stimulation hormone (FSH) 1.6-8.0 miU/mL, Prolactin 4-15 ng/mL
4. Positive Androgen Deficiency in the Aging Male (ADAM) score. A positive score is when an affirmative answer (''yes'') to either questions "Do you have a decreased sex drive/libido?" or "Are your erections less strong?" or any three other questions.10
5. Body mass index (BMI) \<40
6. Sexual health inventory for men (SHIM) score \>7 and \<21. Patients are allowed to be taking phosphodiesterase 5 inhibitors (i.e. Viagra, Levitra, Cialis) at baseline, however we will ask them to do the SHIM survey as if they were not taking this medication.
7. Men must attempt to have at least four sexual encounters over each of the eight-week periods
8. Men willing not to take phosphodiesterase 5 inhibitors throughout the entire study

Exclusion Criteria

1. Current or previous history of prostate cancer
2. Previous or current androgen deprivation therapy for prostate cancer,
3. Past surgical history of prostatectomy.
4. History of testicular cancer.
5. History of deep vein thrombosis (DVT) or blood dyscrasia
6. History of breast cancer
7. Men with past or current treatment for erectile dysfunction including MUSE (alprostodil), intracavernosal injections, penile prosthesis. Men not on treatment or men who are on phosphodiesterase inhibitors will be allowed to be in the study but must stop their use at the screening visit.
8. Chronic opioid use
9. Use of steroids within the past 3 months, including prednisone and/or cortisone injections, and inhaled steroids. Topical steroid cream is acceptable.
10. History of or current use of anabolic steroids, i.e. testosterone, (or any analog of testosterone) dihydroepiandrosterone (DHEA), dihydroepiandrosterone sulfate (DHEAS) or any growth promoters i.e. growth hormone itself or analogs of growth hormone
11. History of or current use of anti-androgen medications, i.e. Aldactone, Tagamet, estrogens
12. Alcohol intake \> 30 grams (drink more than 2 beers per day OR more than 1 glass of wine or cocktail daily)
13. Having started a new medication during the past three months which may interfere with the outcome measures of the study
14. Polycythemia (HCT \>52% )
15. History of prostate specific antigen (PSA)\> 4.0 ng/dl
16. Hematocrit (HCT)\< 36 %
17. Liver function tests greater than 2 times upper normal limits or history of abnormal electrolytes, calcium or Parathyroid hormone without workup, at the discretion of the investigator.
18. Previous hypogonadal treatment within last 3 months. -

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No